Kekkan Biologics

Executive Summary

Kekkan Biologics is a French biotechnology platform company spun out from the University of Nice Côte d'Azur and IRCAN in 2020. The company is developing first-in-class biologics targeting validated pathways in angiogenesis and lymphangiogenesis, with initial focus on severe neovascular and fibrotic disorders, including metastatic cancers. Leveraging the expertise of Dr. Gilles Pagès, Kekkan aims to address high unmet medical needs in diseases driven by abnormal blood and lymphatic vessel formation. The platform's innovative antibody-based approach holds potential for both oncology and fibrotic indications, though the company remains in early preclinical development with no disclosed pipeline candidates or funding rounds as of 2026. Despite its promising scientific foundation, Kekkan Biologics is at a very early stage, with limited public information on specific programs, milestones, or financing. The company's success will depend on advancing its lead candidates through preclinical validation, securing Series A funding, and establishing partnerships. Given the competitive landscape in angiogenesis and fibrosis, Kekkan's differentiation lies in its focus on first-in-class mechanisms. However, significant technical and regulatory hurdles remain. The conviction score reflects the high risk and early stage, balanced by the strong academic pedigree and unmet need.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round50% success
• Q2 2027Lead Candidate Preclinical Proof-of-Concept Data40% success
• 2027Strategic Partnership or Licensing Deal30% success